FR2703053B1 - Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications . - Google Patents

Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .

Info

Publication number
FR2703053B1
FR2703053B1 FR9303514A FR9303514A FR2703053B1 FR 2703053 B1 FR2703053 B1 FR 2703053B1 FR 9303514 A FR9303514 A FR 9303514A FR 9303514 A FR9303514 A FR 9303514A FR 2703053 B1 FR2703053 B1 FR 2703053B1
Authority
FR
France
Prior art keywords
staple
semi
applications
preparation
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9303514A
Other languages
English (en)
Other versions
FR2703053A1 (fr
Inventor
Vasseur Marc
Blumenfeld Marta
Meguenni Said
Poddevin Bruno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to FR9303514A priority Critical patent/FR2703053B1/fr
Priority to PCT/FR1994/000336 priority patent/WO1994023026A1/fr
Priority to AU64320/94A priority patent/AU6432094A/en
Publication of FR2703053A1 publication Critical patent/FR2703053A1/fr
Application granted granted Critical
Publication of FR2703053B1 publication Critical patent/FR2703053B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
FR9303514A 1993-03-26 1993-03-26 Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications . Expired - Fee Related FR2703053B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9303514A FR2703053B1 (fr) 1993-03-26 1993-03-26 Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
PCT/FR1994/000336 WO1994023026A1 (fr) 1993-03-26 1994-03-25 Oligonuclotides agrafes et semi-agrafes, procede de preparation et applications
AU64320/94A AU6432094A (en) 1993-03-26 1994-03-25 Staple and semi-staple oligonucleotides, method of preparation and applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9303514A FR2703053B1 (fr) 1993-03-26 1993-03-26 Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .

Publications (2)

Publication Number Publication Date
FR2703053A1 FR2703053A1 (fr) 1994-09-30
FR2703053B1 true FR2703053B1 (fr) 1995-06-16

Family

ID=9445387

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9303514A Expired - Fee Related FR2703053B1 (fr) 1993-03-26 1993-03-26 Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .

Country Status (3)

Country Link
AU (1) AU6432094A (fr)
FR (1) FR2703053B1 (fr)
WO (1) WO1994023026A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732971B1 (fr) * 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
US20050059016A1 (en) * 2002-11-05 2005-03-17 Ecker David J. Structural motifs and oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
AU6430599A (en) * 1998-10-09 2000-05-01 Cytogenix, Inc. Enzymatic synthesis of ssdna
BR9914773A (pt) * 1998-10-09 2002-02-05 Ingene Inc Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
FR2790757B1 (fr) * 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
WO2002000904A2 (fr) * 2000-06-23 2002-01-03 E. I. Du Pont De Nemours And Company Constructions recombinees et leur utilisation pour reduire l'expression de genes
JP2005511009A (ja) 2001-07-24 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム Ｇｌｙｔ１トランスポーターの新規変異体及びエクソン
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003290596B2 (en) 2002-11-05 2011-05-12 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2004276684A1 (en) * 2003-09-30 2005-04-07 Anges Mg, Inc. Staple type oligonucleotide and drug comprising the same
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
BRPI0519690A2 (pt) * 2004-12-30 2009-03-03 Todd M Hauser composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
EP1986697B1 (fr) * 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions et procédés permettant l'inhibition de silençage de gènes par l'interférence arn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008096A1 (fr) * 1989-01-19 1990-07-19 Samuel Rose Amplification de l'acide nucleique a l'aide d'une amorce unique
NO904633L (no) * 1989-11-09 1991-05-10 Molecular Diagnostics Inc Amplifikasjon av nukleinsyrer ved transkriberbar haarnaalsprobe.
AU654816B2 (en) * 1990-05-04 1994-11-24 Isis Pharmaceuticals, Inc. Modulation of gene expression through interference with RNA secondary structure
NZ239252A (en) * 1990-08-09 1997-07-27 Genta Inc Reagent for attaching a psoralen-containing moiety to an oligonucleotide(derivative); oligonucleotide(derivative)-psoralen conjugates
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides

Also Published As

Publication number Publication date
WO1994023026A1 (fr) 1994-10-13
FR2703053A1 (fr) 1994-09-30
AU6432094A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
FR2703053B1 (fr) Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
FR2680368B1 (fr) Alpha-glycosyl-quercetine, son procede de preparation et ses utilisations.
EP0630972A3 (fr) Procédé d'analyse d'ADN.
DE69623300T2 (de) 2,4 pentadiensaurederivate mit retinoidartigen biologischen aktivität
MA23778A1 (fr) Purine-6-ones-2,9 disubstituees
BR9401355A (pt) Oligonucleotídeo e nucleotídeo.
BR9808730B1 (pt) processo de preparação de 1,1,1,3,3-pentaclorobutano.
FR2704260B1 (fr) Procede de cintrage de parois coffrantes, et parois coffrantes cintrables faisant application de ce procede.
NO960499L (no) Antineurodegenerativt virksomme 10-aminoalifatyldibenz[b,fÅoksepiner
FR2787348B1 (fr) Micro-emulsions, procede de preparation et applications
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
EP0634423A3 (en) Modified acrylonitrile polymers, process for their manufacture and use thereof.
ATA197094A (de) Biorekognitions-gesteuerter, ionenfluss-modulierender biosensor
BR9611040A (pt) Método de fabrição para 1,1,1,3,3-pentaflúorpropano
MA22762A1 (fr) Procede.
MA22980A1 (fr) Procede.
TR199501276A2 (tr) Sübstitüe edilmis sikloalkilamino-ve-alkoksi-heterosaykillar, üretilmelerine mahsus usul ve zararlilarla mücadele maddesi olarak kullanilmalari.
EP0617287A3 (fr) Dosage biospécifique.
MA22761A1 (fr) Procede.
ITMI931785A0 (it) Valilamidi di 7x-amino-1, 1-dioxo-cefem
NL192121B (nl) Valblok.
FI930961A0 (fi) Matstation foer koettboskap, saerskilt svin
ES1030601Y (es) Radiador-convector, perfeccionado.
ES1030930Y (es) Caseton mejorado para forjados.
ES1030661Y (es) Escuadra perfeccionada.

Legal Events

Date Code Title Description
ST Notification of lapse